NewsBenzingaCorMedix Therapeutics 表示，FDA 已接受其提交的 sNDA 申请，寻求批准 REZZAYO 用于侵袭性真菌病预防；PDUFA 目标行动日期定于 2027 年第一季度 CorMedix Therapeutics 表示，FDA 已接受其提交的 sNDA 申请，寻求批准 REZZAYO 用于侵袭性真菌病预防；PDUFA 目标行动日期定于 2027 年第一季度 Benzinga 2026.10.19 11:32 (GMT+0) Open on Benzinga Other news argenx Q3 EPS $7.80 Misses $7.83 Estimate, Sales $1.751B Beat $1.664B Estimate Nokia Q3 Adj. EPS $0.10 Beats $0.08 Estimate, Sales $5.931B Beat $5.800B Estimate Meta reaches deal with Zuckerberg: grants non-voting shares to address California wealth tax, in exchange for 8-year residency Advancements in DRAM, HBM and NAND Driving Technology Leadership in the AI Era eBay China launches large-scale personnel adjustment, with ratio possibly reaching 80% Kingstone: Less Reinsurance Means More Earnings And More Volatility (NASDAQ:KINS)
Meta reaches deal with Zuckerberg: grants non-voting shares to address California wealth tax, in exchange for 8-year residency
